Table 8

Estimated market share (%) of biologic agents for the treatment of moderate to severe psoriasis
Agent Base year Year 1 Year 2 Year 3 Year 4 Year 5
Adalimumab 30 27 25 24 23 23
Etanercept 45 42 39 37 36 35
Infliximab 25 22 20 18 17 16
Ustekinumab 0 9 16 21 24 26

Avgerinou et al.

Avgerinou et al. BMC Dermatology 2012 12:10   doi:10.1186/1471-5945-12-10

Open Data